Lv1
62 积分 2025-02-06 加入
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
15小时前
待确认
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
15小时前
已完结
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2- Breast Cancer
5天前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
27天前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
1个月前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
2个月前
已完结
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
2个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
2个月前
已关闭
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non-Small-Cell Lung Cancer
2个月前
已完结
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
3个月前
已完结
皖公网安备34019202002308
